当前位置：
X-MOL 学术
›
Expert Rev. Anti Infect. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Management strategies for human babesiosis.
Expert Review of Anti-infective Therapy ( IF 4.2 ) Pub Date : 2020-05-04 , DOI: 10.1080/14787210.2020.1752193 Robert P Smith 1 , Klaus-Peter Hunfeld 2 , Peter J Krause 3
更新日期：2020-05-04
Expert Review of Anti-infective Therapy ( IF 4.2 ) Pub Date : 2020-05-04 , DOI: 10.1080/14787210.2020.1752193 Robert P Smith 1 , Klaus-Peter Hunfeld 2 , Peter J Krause 3
Affiliation
Introduction
Human babesiosis is reported throughout the world and is endemic in the northeastern and northern Midwestern United States and northeastern China. Transmission is primarily through hard bodied ticks. Most cases of severe disease occur in immunocompromised individuals and may result in prolonged relapsing disease or death.
Areas covered
We provide a summary of evidence supporting current treatment recommendations for immunocompetent and immunocompromised individuals experiencing babesiosis.
Expert opinion
Most cases of human babesiosis are successfully treated with atovaquone and azithromycin or clindamycin and quinine. Severe disease may require prolonged treatment.
京公网安备 11010802027423号